-
Cytokinetics Inc NASDAQ:CYTK Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Location: 280 E Grand Ave, California, 94080-4808, US | Website: www.cytokinetics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.522B
Cash
1.012B
Avg Qtr Burn
-101.1M
Short % of Float
13.36%
Insider Ownership
0.50%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Aficamten (CK-274) (cardiac myosin inhibitor) Details Heart disease, Hypertrophic cardiomyopathies | NDA Acceptance for review | |
Omecamtiv Mecarbil (cardiac myosin activator) Details Pancreatic cancer, Heart disease, Heart failure | NDA FDA meeting | |
CK-4021586 (CK-586) (cardiac myosin inhibitor) Details Heart disease, Heart failure | Phase 2 Initiation | |
CK-4015089 (CK-089) Details Muscular dystrophy | Phase 1 Data readout | |
CK-3828136(CK-136) (cardiac troponin activator) Details Heart failure, Heart disease, Epilepsy | Phase 1 Data readout | |
Reldesemtiv (CK-601) (next-generation fast skeletal muscle troponin activator (FSTA)) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Failed Discontinued |